Humulin M3 (Mixture 3) (Insulin Human)

Humulin M3 (Mixture 3) is indicated for the management of hyperglycemia in patients with diabetes mellitus.

• Type 1 diabetes mellitus – as part of basal‑bolus insulin regimen.
• Type 2 diabetes mellitus – when diet, exercise, and oral agents are insufficient.
• Adjunct to lifestyle therapy to achieve target glycemic control.
• Use in combination with rapid‑acting insulin analogues for flexible dosing.
• May be used during pregnancy when benefits outweigh risks (note: pregnancy category unknown).
• Can be administered in the hospital setting for rapid correction of hyperglycemia.

• Humulin M3 contains insulin human, a recombinant form of endogenous insulin that binds to insulin receptors on cell membranes. Receptor activation triggers autophosphorylation and initiates intracellular signaling cascades, primarily the phosphoinositide 3‑kinase (PI3K)/Akt pathway, which promotes translocation of glucose transporter type 4 (GLUT4) to the cell surface. This enhances glucose uptake in muscle and adipose tissue and suppresses hepatic glucose production, thereby lowering blood glucose concentrations.

Adverse reactions to Humulin M3 can vary in frequency and severity; understanding the typical and less common events helps patients and clinicians monitor therapy effectively.

Common

• Hypoglycemia (low blood glucose) presenting as sweating, tremor, confusion, or loss of consciousness.
• Injection‑site reactions such as redness, swelling, bruising, or itching.
• Lipodystrophy, including localized fat accumulation (lipohypertrophy) or loss (lipoatrophy) at repeated injection sites.
• Weight gain associated with improved glycemic control and insulin’s anabolic effects.
• Transient headache or mild nausea during dose titration.

Serious

• Severe allergic reactions, including anaphylaxis, bronchospasm, or angioedema.
• Hypersensitivity skin manifestations such as widespread rash, urticaria, or Stevens‑Johnson syndrome.
• Fluid retention leading to peripheral edema or worsening of congestive heart failure.
• Rare episodes of hypokalemia or hyponatremia secondary to rapid glucose shifts.

When prescribing or using Humulin M3, clinicians should consider several precautionary measures to ensure safe and effective therapy.

• Adjust dose in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Monitor blood glucose closely during periods of illness, stress, or changes in diet and physical activity.
• Use lower initial doses in insulin‑naïve individuals to reduce risk of hypoglycemia.
• Evaluate for signs of hypoglycemia before driving or operating machinery.
• Consider pregnancy status; insulin requirements may change and safety data are limited.
• Review patient’s history of allergic reactions to insulin or excipients before initiation.

Humulin M3 may interact with other medicines; recognizing agents that should be avoided or used with caution helps maintain glycemic control and reduce adverse events.

Avoid

• Concurrent use of other rapid‑acting insulin analogues without dose adjustment, which can cause severe hypoglycemia.
• Beta‑blockers, as they may mask hypoglycemia symptoms.
• MAO‑inhibitors, which can potentiate insulin’s glucose‑lowering effect.
• Aliskiren, because combined renal effects may increase risk of hypoglycemia.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which increase hypoglycemia risk.
• Corticosteroids, which raise blood glucose and may require higher insulin doses.
• Thiazide diuretics, which can affect potassium balance and alter insulin sensitivity.
• ACE inhibitors or ARBs, which may require monitoring of renal function and potassium when used with insulin.